Skip to main content
PRGO
NYSE Life Sciences

Perrigo Amends & Restates Credit Agreement, Securing $1.0B Revolving Facility Until 2031

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$9.69
Mkt Cap
$1.317B
52W Low
$9.225
52W High
$28.435
Market data snapshot near publication time

summarizeSummary

Perrigo has amended and restated its credit agreement, securing a new $1.0 billion revolving credit facility with an extended maturity to 2031 and maintaining a $972.4 million term loan B facility, providing critical liquidity and financial flexibility.


check_boxKey Events

  • Amended & Restated Credit Agreement

    Perrigo Company plc entered into an Amended and Restated Credit Agreement on March 20, 2026, replacing an existing agreement from April 20, 2022.

  • New Credit Facilities Established

    The agreement establishes a $1.0 billion revolving credit facility maturing on March 20, 2031, and maintains a $972.4 million term loan B facility maturing on April 20, 2029.

  • Refinancing of Existing Debt

    Proceeds from the new revolving facility will be used to prepay existing Term A Loans in their entirety.

  • Improved Borrowing Terms

    The amendment eliminates the credit spread adjustment applicable to loans under the Revolving Facility, potentially reducing borrowing costs.


auto_awesomeAnalysis

Perrigo has amended and restated its credit agreement, establishing a new $1.0 billion revolving credit facility maturing in March 2031 and maintaining a $972.4 million term loan B facility. This is a significant development for the company, especially in light of its reported $1.43 billion net loss for 2025 and anticipated further impairments. The extension of the revolving facility's maturity provides crucial liquidity and extends the company's financial runway, addressing near-term capital structure risks. The elimination of the credit spread adjustment for the revolving facility also suggests more favorable borrowing terms. The proceeds will be used for refinancing existing Term A Loans, working capital, and general corporate purposes, which are vital for a company navigating financial challenges.

At the time of this filing, PRGO was trading at $9.69 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PRGO - Latest Insights

PRGO
Apr 22, 2026, 4:47 PM EDT
Filing Type: 8-K
Importance Score:
7
PRGO
Mar 23, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
8
PRGO
Mar 20, 2026, 11:33 AM EDT
Filing Type: DEF 14A
Importance Score:
8
PRGO
Feb 26, 2026, 1:34 PM EST
Filing Type: 10-K
Importance Score:
9
PRGO
Feb 26, 2026, 6:38 AM EST
Filing Type: 8-K
Importance Score:
9